<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">2565</journal-id><journal-id journal-id-type="pmc-domain">ancltransneuro</journal-id><journal-id journal-id-type="publisher-id">ACN3</journal-id><journal-title-group><journal-title>Annals of Clinical and Translational Neurology</journal-title></journal-title-group><issn pub-type="epub">2328-9503</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6801158</article-id><article-id pub-id-type="pmcid-ver">PMC6801158.1</article-id><article-id pub-id-type="pmcaid">6801158</article-id><article-id pub-id-type="pmcaiid">6801158</article-id><article-id pub-id-type="pmid">31507085</article-id><article-id pub-id-type="doi">10.1002/acn3.50877</article-id><article-id pub-id-type="publisher-id">ACN350877</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Case Study</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Study</subject></subj-group></article-categories><title-group><article-title>
<sup>11</sup>C‐PK11195 PET imaging and white matter changes in Parkinson’s disease dementia</article-title><alt-title alt-title-type="right-running-head"><sup>11</sup>C‐PK11195 PET and White Matter Changes in PDD</alt-title><alt-title alt-title-type="left-running-head">N. Nicastro <italic toggle="yes">et al</italic>.</alt-title></title-group><contrib-group><contrib id="acn350877-cr-0001" contrib-type="author"><name name-style="western"><surname>Nicastro</surname><given-names initials="N">Nicolas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5836-0792</contrib-id><xref ref-type="aff" rid="acn350877-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="acn350877-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="acn350877-cr-0002" contrib-type="author"><name name-style="western"><surname>Surendranathan</surname><given-names initials="A">Ajenthan</given-names></name><xref ref-type="aff" rid="acn350877-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acn350877-cr-0003" contrib-type="author"><name name-style="western"><surname>Mak</surname><given-names initials="E">Elijah</given-names></name><xref ref-type="aff" rid="acn350877-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acn350877-cr-0004" contrib-type="author"><name name-style="western"><surname>Rowe</surname><given-names initials="JB">James B.</given-names></name><xref ref-type="aff" rid="acn350877-aff-0003">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="acn350877-note-0001">
<sup>†</sup>
</xref></contrib><contrib id="acn350877-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>O’Brien</surname><given-names initials="JT">John T.</given-names></name><xref ref-type="aff" rid="acn350877-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="acn350877-note-0001">
<sup>†</sup>
</xref><address><email>john.obrien@medschl.cam.ac.uk</email></address></contrib></contrib-group><aff id="acn350877-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Cambridge</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="acn350877-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Clinical Neurosciences</named-content>
<institution>Geneva University Hospitals</institution>
<named-content content-type="city">Geneva</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="acn350877-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Clinical Neurosciences</named-content>
<institution>University of Cambridge</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">United Kingdom</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
John O’Brien, Department of Psychiatry, University of Cambridge School of Clinical Medicine, Box 189, Level E4 Cambridge Biomedical Campus, CB2 0SP Cambridge, United Kingdom. Tel: +44 1223 760 682; Fax: +44 1223 336 968; E‐mail: <email>john.obrien@medschl.cam.ac.uk</email><break/></corresp><fn id="acn350877-note-0001"><label>†</label><p>Joint senior authorship.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>6</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">344052</issue-id><issue-id pub-id-type="doi">10.1002/acn3.v6.10</issue-id><fpage>2133</fpage><lpage>2136</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>02</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>09</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>22</day><month>10</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-12-11 12:16:19.717"><day>11</day><month>12</month><year>2020</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2019 The Authors. <italic toggle="yes">Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals, Inc on behalf of American Neurological Association.</copyright-statement><license license-type="creativeCommonsBy"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ACN3-6-2133.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ACN3-6-2133.pdf"/><abstract id="acn350877-abs-0001"><title>Abstract</title><p>There is evidence of increased microglial activation in Parkinson’s disease (PD) as shown by in vivo PET ligand such as <sup>11</sup>C‐PK11195. In addition, diffusion tensor imaging (DTI) imaging reveals widespread changes in PD, especially when the associated dementia develops. In the present case series, we studied five subjects with Parkinson’s disease dementia (PDD). Our findings suggest that while DTI metrics mirror cognitive severity, higher <sup>11</sup>C‐PK11195 binding seems to be associated with a relative preservation of both white matter tracts and cognition. Longitudinal studies are warranted to tackle the complex relationship between microglial activation and structural abnormalities in neurodegenerative conditions.</p></abstract><funding-group><award-group><funding-source>Alzheimer's Research UK</funding-source></award-group><award-group><funding-source>Wellcome Trust</funding-source><award-id>103838</award-id></award-group><award-group><funding-source>NIHR Cambridge Biomedical Research Center</funding-source><award-id>RG64473</award-id></award-group><funding-statement>This work was funded by <funding-source>Alzheimer's Research UK</funding-source> grant ; <funding-source>Wellcome Trust</funding-source> grant <award-id>103838</award-id>; <funding-source>NIHR Cambridge Biomedical Research Center</funding-source> grant <award-id>RG64473</award-id>. </funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="4"/><word-count count="1729"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>acn350877</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.7.0 mode:remove_FC converted:20.10.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acn350877-ntgp-0001"><fn fn-type="funding" id="acn350877-note-0002"><p>
<bold>Funding Information</bold>
</p><p>We thank Alzheimer's Research UK, the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR, RG64473), and the Wellcome Trust (JBR: 103838) for funding and support.</p></fn></fn-group></notes></front><body><sec id="acn350877-sec-0001"><title>Introduction</title><p>Neuroinflammation is increasingly recognized as a key contributor to neurodegeneration in Parkinson’s disease (PD) and dementia.<xref rid="acn350877-bib-0001" ref-type="ref">1</xref> PET probes have been developed to assess in vivo brain inflammation, for example, by targeting translocator protein (TSPO).<xref rid="acn350877-bib-0002" ref-type="ref">2</xref> Among those, <sup>11</sup>C‐PK11195 is one of the most widely used ligands to estimate microglial activation.<xref rid="acn350877-bib-0003" ref-type="ref">3</xref> Recent studies in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) have shown that microglial activation, as measured with <sup>11</sup>C‐PK11195 PET, is more prominent in patients at an earlier disease stage.<xref rid="acn350877-bib-0004" ref-type="ref">4</xref>, <xref rid="acn350877-bib-0005" ref-type="ref">5</xref> Diffusion tensor imaging (DTI), on the other hand, is an application of diffusion‐weighted magnetic resonance imaging designed to assess microstructural integrity based on motion of water molecules. Impaired white matter integrity in people with PD has been consistently observed in corpus callosum, in relation to cognitive impairment and development of dementia.<xref rid="acn350877-bib-0006" ref-type="ref">6</xref>, <xref rid="acn350877-bib-0007" ref-type="ref">7</xref> In the present case series, we studied <sup>11</sup>C‐PK11195 binding as an index of neuroinflammation, and its association with DTI, motor, and cognitive features of Parkinson’s disease dementia (PDD).</p></sec><sec id="acn350877-sec-0002"><title>Subjects and Methods</title><p>We studied five PDD subjects who were recruited within the Neuroimaging of Inflammation in Memory and other Disorders (NIMROD) study protocol.<xref rid="acn350877-bib-0008" ref-type="ref">8</xref> Demographics are available in Table <xref rid="acn350877-tbl-0001" ref-type="table">1</xref>. Each subject underwent structural MRI, 3T DTI, and <sup>11</sup>C‐PK11195 PET imaging, as well as in‐depth neuropsychological and motor assessment, including Addenbrooke's Cognitive Evaluation Revised (ACER) and Movement Disorders Society (MDS) Unified Parkinson’s Disease Rating Scale (UPDRS) part III motor assessment.</p><table-wrap id="acn350877-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics, clinical, and imaging features of included PDD subjects.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Subject</th><th align="left" valign="top" rowspan="1" colspan="1">Age (years), Gender</th><th align="left" valign="top" rowspan="1" colspan="1">MDS‐UPDRS III, <italic toggle="yes">ON‐state</italic>
</th><th align="left" valign="top" rowspan="1" colspan="1">ACER</th><th align="left" valign="top" rowspan="1" colspan="1">DTI global radial diffusivity</th><th align="left" valign="top" rowspan="1" colspan="1">Significant <sup>11</sup>C‐PK11195 BP<sub>ND</sub> changes compared to Controls</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PDD 1</td><td align="left" rowspan="1" colspan="1">78, M</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">5.11 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1">Putamen (↑), substantia nigra (↓)</td></tr><tr><td align="left" rowspan="1" colspan="1">PDD 2</td><td align="left" rowspan="1" colspan="1">70, M</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">5.36 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1">Parahippocampal gyrus (↓)</td></tr><tr><td align="left" rowspan="1" colspan="1">PDD 3</td><td align="left" rowspan="1" colspan="1">70, M</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">6.19 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1">Substantia nigra (↓)</td></tr><tr><td align="left" rowspan="1" colspan="1">PDD 4</td><td align="left" rowspan="1" colspan="1">81, M</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">6.09 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1">Midbrain (↓), medulla (↓)</td></tr><tr><td align="left" rowspan="1" colspan="1">PDD 5</td><td align="left" rowspan="1" colspan="1">68, M</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">4.83 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1">Mesial anterior temporal lobe (↓), fusiform gyrus (↓), superior parietal gyrus (↓), lateral orbital gyrus (↓), amygdala (↓), nucleus accumbens (↓), substantia nigra (↓), pons (↓)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean ± SD</td><td align="left" rowspan="1" colspan="1">73.4 ± 5.7</td><td align="left" rowspan="1" colspan="1">38.8 ± 5.6</td><td align="left" rowspan="1" colspan="1">79.2 ± 7.0</td><td align="left" rowspan="1" colspan="1">5.52 × 10<sup>−4</sup>
</td><td align="left" rowspan="1" colspan="1"> </td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Mean cortical thickness was obtained with Freesurfer 6.0 using the standard processing pipeline described in.<xref rid="acn350877-bib-0009" ref-type="ref">9</xref> DTI imaging was processed with FSL 6.0.<xref rid="acn350877-bib-0010" ref-type="ref">10</xref> Briefly, this included registration of all diffusion‐weighted images to the <italic toggle="yes">b</italic> = 0 (i.e., no diffusion) volume using the FMRIB Software Library (FSL) Diffusion Toolbox, followed by brain masks creation with <italic toggle="yes">Brain Extraction Tool</italic>, head movement, and eddy currents correction. We then used <italic toggle="yes">DTIfit</italic> to independently fit the diffusion tensor for each voxel, resulting in the derivation of fractional anisotropy (FA), mean and radial diffusivity (MD and RD, respectively).</p><p>Details about <sup>11</sup>C‐PK11195 PET processing are available in<xref rid="acn350877-bib-0004" ref-type="ref">4</xref>. In brief, binding in each region of interest was quantified using non‐displaceable binding potential (BP<sub>ND</sub>) determined with a simplified reference tissue model incorporating vascular binding correction and reference region time‐activity curve estimation from supervised cluster analysis using four kinetic classes. Regional BP<sub>ND</sub> was corrected for CSF contamination through division of the region of interest time‐activity curve with the mean region of interest fraction of grey and white matter. Regional BP<sub>ND</sub> binding was obtained for each subject with the Hammers atlas.<xref rid="acn350877-bib-0004" ref-type="ref">4</xref>, <xref rid="acn350877-bib-0011" ref-type="ref">11</xref>
</p><p>Subsequently, regional <sup>11</sup>C‐PK11195 binding Z‐scores were computed by comparing each PDD subject’s values to 16 similarly aged control subjects (mean ± SD age 69.7 ± 6.6 years, 50% female participants, ACER score 92.5 ± 5.6) scanned with the same imaging protocol,<xref rid="acn350877-bib-0002" ref-type="ref">2</xref> with <italic toggle="yes">Z</italic>‐scores higher/lower than 2.0 considered as significant. Spearman correlations and regression analyses were performed in the PDD group between composite lobar (frontal, temporal, parietal, occipital) and whole‐cortex <sup>11</sup>C‐PK11195 BP<sub>ND</sub>, DTI metrics, and clinical data. Given the exploratory design of the study, results were not corrected for multiple comparisons.</p></sec><sec sec-type="results" id="acn350877-sec-0003"><title>Results</title><p>Demographics and main findings are available in Table <xref rid="acn350877-tbl-0001" ref-type="table">1</xref>. The analyses revealed that PDD subjects had comparable or lower levels of whole‐cortex as well as regional <sup>11</sup>C‐PK11195 binding relative to controls (Fig. <xref rid="acn350877-fig-0001" ref-type="fig">1</xref>). In addition, lobar occipital <sup>11</sup>C‐PK11195 binding was inversely correlated with MD and RD after adjusting for mean cortical thickness (<italic toggle="yes">linear regression</italic>, for MD: <italic toggle="yes">B</italic> = −415.6, <italic toggle="yes">P</italic> = 0.035, adjusted <italic toggle="yes">R</italic>
<sup>2</sup> = 0.89; for RD: B coefficient = −348.6, <italic toggle="yes">P</italic> = 0.032, adjusted <italic toggle="yes">R</italic>
<sup>2</sup> = 0.90), that is, higher <sup>11</sup>C‐PK11195 was associated with a relative preservation of white matter integrity. The directionality of these PET‐MRI correlations was congruent with those from neuropsychological data. In fact, ACER score positively correlated with frontal <sup>11</sup>C‐PK11195 binding when adjusting for mean cortical thickness (<italic toggle="yes">linear regression</italic>, <italic toggle="yes">B</italic> = 641.2, <italic toggle="yes">P</italic> = 0.014, adjusted <italic toggle="yes">R</italic>
<sup>2</sup> = 0.95). In addition, there was a trend for higher ACER scores being related to preserved DTI metrics (lower MD/RD and higher FA, Spearman <italic toggle="yes">P</italic> = 0.10, rho = −0.80 for MD/RD and 0.80 for FA). There was no significant association between MDS‐UPDRS part III score and <sup>11</sup>C‐PK11195 binding or DTI metrics.</p><fig fig-type="Figure" xml:lang="en" id="acn350877-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Axial <sup>11</sup>C‐PK11195 BP<sub>ND</sub> images and T1‐weighted structural MRI of the five PDD included in the study and one representative control subject (65‐year‐old female participant, ACER 96/100). PDD patients have similar <sup>11</sup>C‐PK11195 binding than the control participants, except PDD 5 who has lower binding values in several regions (cf. Table <xref rid="acn350877-tbl-0001" ref-type="table">1</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="nlm-graphic-1" position="float" orientation="portrait" xlink:href="ACN3-6-2133-g001.jpg"/></fig></sec><sec sec-type="discussion" id="acn350877-sec-0004"><title>Discussion</title><p>Our study suggests that higher <sup>11</sup>C‐PK11195 binding is associated with a relative preservation of both white matter tracts and cognition. Specifically, we found that DTI metrics mirror disease severity, and that PDD subjects had similar or reduced <sup>11</sup>C‐PK11195 binding compared to controls.<xref rid="acn350877-bib-0006" ref-type="ref">6</xref>, <xref rid="acn350877-bib-0012" ref-type="ref">12</xref> While these findings require confirmation with larger samples, longitudinal data, and finer imaging proxies (e.g., voxel‐wise DTI association with <sup>11</sup>C‐PK11195 binding), this case series brings novel evidence for an early role of neuroinflammation in the pathophysiology of PDD and confers additional support for the hypothesis that central inflammation represents a potential therapeutic target in dementia.</p></sec><sec id="acn350877-sec-0006"><title>Author Contributions</title><p>Nicolas Nicastro contributed to research project execution, data review and critique, and manuscript draft. Ajenthan Surendranathan also contributed to research project execution, data review, and manuscript review. Elijah Mak contributed to research project execution, data review, and manuscript review. James B. Rowe contributed to research project conception, organization and execution, data review, and manuscript review. John T. O’Brien contributed to research project conception, organization and execution, data review, and manuscript review.</p></sec><sec sec-type="COI-statement" id="acn350877-sec-0007"><title>Conflict of Interest</title><p>The authors have no conflict of interest to report.</p></sec></body><back><ack id="acn350877-sec-0005"><title>Acknowledgments</title><p>We are grateful to our volunteers for their participation in the study. We thank the radiographers at Wolfson Brain Imaging Centre and the PET/CT unit, Addenbrooke's Hospital for their technical expertise and support in data acquisition. We thank Alzheimer Research UK, the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR, RG64473), and the Wellcome Trust (JBR: 103838) for funding and support.</p></ack><ref-list content-type="cited-references" id="acn350877-bibl-0001"><title>References</title><ref id="acn350877-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acn350877-cit-0001"><string-name name-style="western"><surname>Edison</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Z</given-names></string-name>, et al. <article-title>Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia</article-title>. <source xml:lang="en">Neuropsychopharmacology</source><year>2013</year>;<volume>38</volume>:<fpage>938</fpage>–<lpage>949</lpage>.<pub-id pub-id-type="pmid">23303049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2012.255</pub-id><pub-id pub-id-type="pmcid">PMC3629382</pub-id></mixed-citation></ref><ref id="acn350877-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acn350877-cit-0002"><string-name name-style="western"><surname>Stefaniak</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>J</given-names></string-name>. <article-title>Imaging of neuroinflammation in dementia: a review</article-title>. <source xml:lang="en">J Neurol Neurosurg Psychiatry</source><year>2016</year>;<volume>87</volume>:<fpage>21</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">26384512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2015-311336</pub-id></mixed-citation></ref><ref id="acn350877-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acn350877-cit-0003"><string-name name-style="western"><surname>Cagnin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>AM</given-names></string-name>, et al. <article-title>In‐vivo measurement of activated microglia in dementia</article-title>. <source xml:lang="en">Lancet</source><year>2001</year>;<volume>358</volume>:<fpage>461</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">11513911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(01)05625-2</pub-id></mixed-citation></ref><ref id="acn350877-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acn350877-cit-0004"><string-name name-style="western"><surname>Surendranathan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mak</surname><given-names>E</given-names></string-name>, et al. <article-title>Early microglial activation and peripheral inflammation in dementia with Lewy bodies</article-title>. <source xml:lang="en">Brain</source><year>2018</year>;<volume>141</volume>:<fpage>3415</fpage>–<lpage>3427</lpage>.<pub-id pub-id-type="pmid">30403785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy265</pub-id><pub-id pub-id-type="pmcid">PMC6262214</pub-id></mixed-citation></ref><ref id="acn350877-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acn350877-cit-0005"><string-name name-style="western"><surname>Femminella</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Dani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>M</given-names></string-name>, et al. <article-title>Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume</article-title>. <source xml:lang="en">Neurology</source><year>2019</year>;<volume>92</volume>:<fpage>e1331</fpage>–<lpage>e1343</lpage>.<pub-id pub-id-type="pmid">30796139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007133</pub-id><pub-id pub-id-type="pmcid">PMC6511099</pub-id></mixed-citation></ref><ref id="acn350877-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acn350877-cit-0006"><string-name name-style="western"><surname>Minett</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mak</surname><given-names>E</given-names></string-name>, et al. <article-title>Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE‐PD study</article-title>. <source xml:lang="en">J Neurol</source><year>2018</year>;<volume>265</volume>:<fpage>1528</fpage>–<lpage>1539</lpage>.<pub-id pub-id-type="pmid">29696499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-018-8873-0</pub-id></mixed-citation></ref><ref id="acn350877-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acn350877-cit-0007"><string-name name-style="western"><surname>Kamagata</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tomiyama</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Motoi</surname><given-names>Y</given-names></string-name>, et al. <article-title>Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: comparison with conventional diffusion tensor imaging</article-title>. <source xml:lang="en">Magn Reson Imaging</source><year>2013</year>;<volume>31</volume>:<fpage>1501</fpage>–<lpage>1506</lpage>.<pub-id pub-id-type="pmid">23895870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2013.06.009</pub-id></mixed-citation></ref><ref id="acn350877-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acn350877-cit-0008"><string-name name-style="western"><surname>Bevan‐Jones</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Surendranathan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Passamonti</surname><given-names>L</given-names></string-name>, et al. <article-title>Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses</article-title>. <source xml:lang="en">BMJ Open</source><year>2017</year>;<volume>7</volume>:<elocation-id>e013187</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2016-013187</pub-id><pub-id pub-id-type="pmcid">PMC5223666</pub-id><pub-id pub-id-type="pmid">28064175</pub-id></mixed-citation></ref><ref id="acn350877-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acn350877-cit-0009"><string-name name-style="western"><surname>Fischl</surname><given-names>B</given-names></string-name>. <article-title>FreeSurfer</article-title>. <source xml:lang="en">Neuroimage</source><year>2012</year>;<volume>62</volume>:<fpage>774</fpage>–<lpage>781</lpage>.<pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.01.021</pub-id><pub-id pub-id-type="pmcid">PMC3685476</pub-id></mixed-citation></ref><ref id="acn350877-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acn350877-cit-0010"><string-name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beckmann</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Behrens</surname><given-names>TE</given-names></string-name>, et al. <article-title>Fsl</article-title>. <source xml:lang="en">Neuroimage</source><year>2012</year>;<volume>62</volume>:<fpage>782</fpage>–<lpage>790</lpage>.<pub-id pub-id-type="pmid">21979382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.09.015</pub-id></mixed-citation></ref><ref id="acn350877-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acn350877-cit-0011"><string-name name-style="western"><surname>Hammers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Allom</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Koepp</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe</article-title>. <source xml:lang="en">Hum Brain Mapp</source><year>2003</year>;<volume>19</volume>:<fpage>224</fpage>–<lpage>247</lpage>.<pub-id pub-id-type="pmid">12874777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.10123</pub-id><pub-id pub-id-type="pmcid">PMC6871794</pub-id></mixed-citation></ref><ref id="acn350877-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acn350877-cit-0012"><string-name name-style="western"><surname>Varnas</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cselenyi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jucaite</surname><given-names>A</given-names></string-name>, et al. <article-title>PET imaging of [(11)C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding</article-title>. <source xml:lang="en">Eur J Nucl Med Mol Imaging</source><year>2019</year>;<volume>46</volume>:<fpage>367</fpage>–<lpage>375</lpage>.<pub-id pub-id-type="pmid">30270409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-018-4161-6</pub-id><pub-id pub-id-type="pmcid">PMC6333720</pub-id></mixed-citation></ref></ref-list></back></article>